Genetic mutations, pathology, and single-nucleus transcriptomic landscape in LVHT patients reveal differential

Yifan Wang1, Weiteng Wang1, Han Mo1

  • 1Beijing Key Laboratory of Preclinical Research & Evaluation for Cardiovascular Implant Materials, Animal Experimental Centre, National Centre for Cardiovascular Disease, Department of Cardiac Surgery, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Insights

Left ventricular hypertrabeculation/non-compaction (LVHT) progression to heart transplantation is linked to specific transcriptomic and pathological features. The Notch pathway molecule MAML3 may indicate disease advancement in LVHT patients.

Area of Science:

  • Cardiology
  • Genetics
  • Molecular Biology

Background:

  • Left ventricular hypertrabeculation/non-compaction (LVHT) presents unique cardiac morphology but variable clinical outcomes.
  • Factors driving LVHT progression to heart transplantation are not well understood.
  • No prior studies linked LVHT transcriptomic or pathological features to transplantation progression.

Purpose of the Study:

  • To investigate the transcriptomic and pathological features of LVHT.
  • To determine factors influencing LVHT progression to heart transplantation.
  • To identify potential biomarkers for disease progression.

Main Methods:

  • Whole-exome sequencing in 74 LVHT patients.
  • Single-nucleus RNA sequencing on explanted LVHT hearts.
  • Histopathological analysis of myocardial composition, fibrosis, and non-compaction.

Main Results:

  • Genetic variants found in 46% of patients, not linked to transplantation.
  • Transcriptional profiles of compacted and non-compacted LVHT layers were similar.
  • Notch signaling was enriched; MAML3 upregulation correlated with faster progression to transplantation.
  • Fibrosis and non-compaction distribution linked to cardiac function and transplant outcomes.

Conclusions:

  • LVHT exhibits distinct transcriptomic and pathological features impacting heart transplantation progression rates.
  • The Notch pathway molecule MAML3 shows potential as a marker for LVHT disease progression.
Abstract

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
362
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
668
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
313